ERBB2 and osteosarcoma: When treated with trastuzumab, SaoS-2, an established osteosarcoma cell line, manifested growth inhibition similar to that observed for HER-2-positive breast cancer cell lines.[6] Nevertheless, studies investigating HER-2 expression in patient samples reported conflicting results.